List of Excipients in Branded Drug TRUQAP

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AstraZeneca Pharmaceuticals LP	TRUQAP	capivasertib	0310-9500	ANHYDROUS DIBASIC CALCIUM PHOSPHATE	2033-04-16
AstraZeneca Pharmaceuticals LP	TRUQAP	capivasertib	0310-9500	CELLULOSE, MICROCRYSTALLINE	2033-04-16
AstraZeneca Pharmaceuticals LP	TRUQAP	capivasertib	0310-9500	COPOVIDONE K25-31	2033-04-16
AstraZeneca Pharmaceuticals LP	TRUQAP	capivasertib	0310-9500	CROSCARMELLOSE SODIUM	2033-04-16
AstraZeneca Pharmaceuticals LP	TRUQAP	capivasertib	0310-9500	FERRIC OXIDE RED	2033-04-16
AstraZeneca Pharmaceuticals LP	TRUQAP	capivasertib	0310-9500	FERRIC OXIDE YELLOW	2033-04-16

TRUQAP Excipient Strategy and Commercial Opportunities for Capivasertib Tablets

Last updated: September 24, 2026

TRUQAP (capivasertib) is an AstraZeneca oral kinase inhibitor approved by the FDA for adults with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer carrying one or more PIK3CA, AKT1, or PTEN alterations after progression on at least one endocrine-based regimen. It is administered with fulvestrant at 400 mg twice daily for four days followed by three days off treatment.[1]

The commercial opportunity is concentrated in four areas: reliable supply of the current excipients, lower-cost generic formulation development, differentiated oral dosage forms, and formulation or manufacturing intellectual property. The marketed product uses conventional tablet excipients, which reduces technical barriers to generic development but leaves room for cost, process, stability, and patient-adherence improvements.

What excipients are used in TRUQAP tablets?

TRUQAP uses a conventional immediate-release, film-coated tablet platform.

Formulation element	Reported excipient or material	Primary technical function
Tablet core	Mannitol	Diluent and bulking agent
Tablet core	Microcrystalline cellulose	Diluent, dry binder, compression aid
Tablet core	Croscarmellose sodium	Superdisintegrant
Tablet core	Sodium lauryl sulfate	Wetting and solubilization aid
Tablet core	Colloidal silicon dioxide	Glidant and flow aid
Tablet core	Magnesium stearate	Lubricant
Film coating	Hypromellose	Film-forming polymer
Film coating	Titanium dioxide	Opacifier and pigment
Film coating	Talc	Anti-tacking and coating-process aid
Film coating	Iron oxide pigment	Tablet identification and color control

The inactive ingredients are identified in the FDA prescribing information for TRUQAP. The label does not disclose quantitative excipient concentrations, manufacturing process parameters, granulation conditions, particle-size specifications, or supplier identities.[1]

What is the likely function of the TRUQAP excipient system?

The formulation is designed for robust tablet manufacture rather than modified release.

Mannitol and microcrystalline cellulose provide the tablet mass and support direct compression or a related dry-processing approach. Croscarmellose sodium promotes rapid tablet breakup after administration. Sodium lauryl sulfate improves wetting of the active pharmaceutical ingredient, which may have limited aqueous solubility. Colloidal silicon dioxide improves powder flow, while magnesium stearate reduces tooling adhesion and ejection force.

The film coat protects the tablet surface, supports identification of the two marketed strengths, and improves handling. The excipient set does not indicate an extended-release, enteric-coated, osmotic, or multiparticulate delivery system.

What excipient strategy is most relevant for TRUQAP?

The highest-value strategy is to preserve immediate-release performance while improving manufacturability, supply resilience, and cost.

1. Maintain a low-complexity immediate-release platform

A generic developer would likely begin with the listed excipient architecture because it is familiar, commercially available, and compatible with conventional solid-dose manufacturing. Substitution risk is manageable for mannitol, microcrystalline cellulose, croscarmellose sodium, silica, and magnesium stearate, provided the finished product matches the reference product in dissolution, disintegration, potency, content uniformity, and stability.

The core development questions are:

• Whether the drug substance requires wetting enhancement.
• Whether sodium lauryl sulfate is needed at the reference level.
• Whether direct compression provides sufficient content uniformity.
• Whether lubricant concentration affects dissolution.
• Whether mannitol creates polymorphic, hygroscopicity, or compaction issues.
• Whether the coating pigment system affects process control or regulatory comparability.

2. Use excipient grade as a performance variable

Excipient substitution is not automatically interchangeable. Differences in particle size, moisture, bulk density, degree of substitution, and surface area can change tablet hardness and dissolution.

Relevant controls include:

Excipient	Critical attributes
Mannitol	Particle-size distribution, polymorphic form, moisture, compactability
Microcrystalline cellulose	Grade, moisture, bulk density, compressibility
Croscarmellose sodium	Degree of substitution, swelling capacity, particle size
Sodium lauryl sulfate	Purity, residual solvents, particle size, wetting performance
Colloidal silicon dioxide	Surface area, moisture, flow performance
Magnesium stearate	Specific surface area, fatty-acid profile, lubrication efficiency
Hypromellose	Viscosity grade, substitution pattern, coating viscosity
Talc and pigments	Particle size, purity, color consistency, coating suspension stability

A supplier change could require comparative dissolution and stability work even where the excipient name remains unchanged. For a high-value oncology product, dual sourcing is commercially attractive because manufacturing interruptions can affect treatment continuity and hospital or specialty-pharmacy supply.

3. Optimize sodium lauryl sulfate exposure

Sodium lauryl sulfate is the most strategically important excipient in the formulation because it may materially affect wetting and dissolution. It can also create development constraints related to compatibility, lubrication, residual surfactant, and patient acceptability.

A generic or reformulation developer could test:

• Lower sodium lauryl sulfate concentrations.
• Alternative surfactants such as polysorbate systems or sodium docusate, subject to compatibility and regulatory acceptability.
• Wetting through particle engineering or drug-substance size reduction.
• Co-processing with a hydrophilic carrier.
• Spray-dried or crystalline drug-substance intermediates.
• Amorphous solid-dispersion approaches if the solubility profile warrants them.

A lower-surfactant formulation would have commercial value if it preserves exposure while reducing raw-material cost, process variability, or sensitivity to tablet compression. It would also create potential formulation intellectual property if the performance advantage is unexpected and supported by comparative data.

What formulation patents could protect TRUQAP alternatives?

The current product’s public label identifies excipients but does not establish the scope of AstraZeneca’s formulation or process patent claims. A commercial freedom-to-operate review must distinguish patents covering capivasertib itself from patents covering a particular tablet, solid form, process, or use.

Potential claim categories include:

1. Active pharmaceutical ingredient patents. These may cover capivasertib composition, chemical intermediates, or specific salts and solid forms.
2. Solid-state patents. Crystalline forms, polymorphs, solvates, hydrates, and particle-size distributions can affect generic timing.
3. Formulation patents. Claims may cover specific ratios of capivasertib to mannitol, cellulose, disintegrant, surfactant, or lubricant.
4. Process patents. Dry granulation, wet granulation, milling, blending, compression, and coating conditions may be claimed.
5. Method-of-use patents. Indications based on PIK3CA, AKT1, or PTEN alterations, endocrine-resistance status, dosing schedules, or combinations with fulvestrant may create litigation exposure.
6. Combination-product patents. A co-pack or fixed-dose approach involving capivasertib and fulvestrant could raise separate formulation and use questions.

The strongest formulation opportunity is unlikely to be a simple substitution of one conventional excipient for another. Stronger claims would connect a defined excipient range or process condition to an unexpected result, such as improved dissolution after accelerated storage, reduced food sensitivity, lower tablet weight, or improved content uniformity.

When does TRUQAP lose FDA exclusivity?

TRUQAP received FDA approval on November 16, 2023.[2] As a new chemical entity, it generally receives five years of FDA marketing exclusivity, subject to statutory exceptions and any pediatric extension.

Regulatory right	Approximate date or status
FDA approval	November 16, 2023
Five-year NCE exclusivity	Generally through November 16, 2028
Earliest typical ANDA filing with Paragraph IV certification	Approximately November 16, 2027, subject to applicable patent listings
Earliest possible generic approval based solely on NCE timing	Generally no earlier than November 16, 2028, absent a successful challenge or other statutory pathway
Pediatric six-month extension	Not assumed without an FDA-granted extension
Orange Book patent expiry	Requires confirmation from the current FDA Orange Book and patent records

NCE exclusivity is distinct from patent protection. A generic applicant could file a Paragraph IV certification against listed patents after the relevant filing window opens. A successful Paragraph IV challenge could accelerate entry before the latest listed patent expiry, while a valid patent could delay approval even after NCE exclusivity ends.

What is the Orange Book status of TRUQAP?

TRUQAP is an FDA-approved small-molecule drug and is eligible for Orange Book listing of patents that meet FDA listing requirements. The Orange Book may include patents covering the active ingredient, formulation, or approved methods of use. Listing status can change through patent submissions, delistings, FDA review, and updates to the electronic Orange Book.[3]

Commercial diligence should verify:

• Each listed patent number.
• Patent use codes.
• Expiration dates, including patent-term adjustment.
• Any pediatric exclusivity extension.
• Whether a patent is listed against the 160 mg tablet, 200 mg tablet, treatment regimen, or approved indication.
• Any Paragraph IV notice letters or district-court complaints.
• Any 30-month stay triggered by a timely infringement action.

No conclusion about generic entry timing should be based solely on the five-year NCE period.

Which companies are likely to challenge TRUQAP?

The likely challengers are established generic manufacturers with oncology portfolios and experience with complex oral solid-dose products. Candidate commercial participants include large U.S. generic companies, Indian manufacturers with ANDA capabilities, and contract development and manufacturing organizations seeking formulation-development partnerships.

The principal entry models are:

• An ANDA for a conventional immediate-release tablet.
• A Paragraph IV challenge to listed drug or formulation patents.
• A Section viii carve-out for one or more method-of-use claims.
• A later launch after patent expiry without litigation.
• A licensed generic or authorized-generic arrangement.
• A regional product outside the United States.

Because capivasertib is a small molecule rather than a biologic, biosimilar risk is not relevant. The competitive issue is generic substitution, not interchangeability under the biosimilar pathway.

What commercial opportunities exist for excipient suppliers?

The addressable opportunity is broader than supplying the exact ingredients listed in the label.

Qualified excipient supply

Suppliers can compete on:

• Consistent mannitol and microcrystalline cellulose grades.
• Low-variability croscarmellose sodium.
• Pharmaceutical-grade sodium lauryl sulfate.
• High-flow colloidal silicon dioxide.
• Low-moisture magnesium stearate.
• Ready-to-use coating systems.
• Dual-source and regional supply.
• Regulatory documentation and change-control support.

A supplier that provides a matched excipient platform with validated processing data may have greater value than a supplier offering a lower unit price alone.

Co-processed excipients

Co-processed systems combining a filler, binder, and disintegrant could reduce blending steps and improve flow or compactability. Their commercial potential depends on whether the formulation can reproduce the reference product’s dissolution profile and support a defensible regulatory package.

Film-coating systems

A ready-to-use hypromellose coating system with matched opacity, color, adhesion, and drying behavior could simplify manufacturing. The opportunity is strongest for contract manufacturers and generic developers that want to reduce coating development time across both TRUQAP strengths.

Manufacturing and process development

Capivasertib tablet development may create demand for:

• Low-shear blending.
• Dry granulation.
• Continuous manufacturing.
• In-line weight and hardness monitoring.
• Automated coating control.
• Drug-substance particle engineering.
• Scale-up support for commercial batches.

Process intellectual property can be more defensible than an unremarkable excipient substitution if it reduces variability or improves stability at commercial scale.

How does TRUQAP compare with competing targeted breast-cancer drugs?

TRUQAP competes with other targeted therapies used in hormone receptor-positive, HER2-negative advanced breast cancer, including alpelisib, everolimus, and oral selective estrogen receptor degraders in applicable settings.

Product	Active ingredient	Dosage form	Excipient opportunity
TRUQAP	Capivasertib	Immediate-release film-coated tablet	Wetting, dissolution, supply resilience, coating
PIQRAY	Alpelisib	Film-coated tablet	Oral solid-dose and specialty oncology manufacturing
Afinitor	Everolimus	Tablet and dispersible tablet options	Solubility, low-dose content uniformity, dispersible formats
Orserdu	Elacestrant	Film-coated tablet	Conventional tablet supply and adherence formats

TRUQAP’s differentiated market position is tied to AKT pathway inhibition and biomarker-selected treatment. Its excipient opportunity is less about creating a new delivery route and more about maintaining reliable exposure in a conventional oral product.

What generic launch scenarios exist for TRUQAP?

Three launch scenarios are commercially credible.

Scenario 1: Routine post-exclusivity entry

A generic developer launches after NCE exclusivity and relevant patent barriers expire. This is the lowest litigation-risk scenario but may produce several entrants and rapid price erosion.

Scenario 2: Paragraph IV challenge

A challenger argues that one or more listed patents are invalid, unenforceable, or not infringed. The commercial upside is greater because an early entrant can obtain 180-day exclusivity in the applicable circumstances, but litigation costs and launch uncertainty are substantial.

Scenario 3: Formulation differentiation

A developer introduces a product with improved manufacturability, a lower-cost excipient system, or an alternative dosage form. The product still must satisfy applicable FDA requirements for therapeutic equivalence or approval under another pathway. A materially different formulation may fall outside a simple ANDA strategy and require a 505(b)(2) application.

A fixed-dose capivasertib-fulvestrant product would face major technical and regulatory hurdles because fulvestrant is administered by intramuscular injection, while capivasertib is oral. A co-packaged regimen is more feasible than a true fixed-dose product but would need to demonstrate commercial and adherence value.

How strong is the TRUQAP formulation opportunity?

The formulation opportunity is moderate. The product uses familiar excipients and a conventional film-coated tablet, which lowers development complexity and supports generic competition. The main barriers are likely to arise from active-ingredient patents, solid-state protection, method-of-use claims, bioequivalence, and supply-chain qualification rather than from unusual excipients.

The strongest commercial positions are:

1. A validated low-cost formulation with equivalent dissolution and stability.
2. A dual-source excipient supply package for AstraZeneca or contract manufacturers.
3. A capivasertib formulation with improved wetting and reduced surfactant dependence.
4. A process platform that improves content uniformity or scale-up.
5. A regional or specialty-generic product launched after exclusivity and patent review.

Key Takeaways

• TRUQAP is a conventional immediate-release film-coated capivasertib tablet.
• The listed excipients are mannitol, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate, and standard coating materials.
• Sodium lauryl sulfate is the most important formulation variable because it may control wetting and dissolution.
• NCE exclusivity generally runs through November 16, 2028, subject to statutory exceptions and any pediatric extension.
• Generic entrants may pursue Paragraph IV challenges, Section viii carve-outs, or post-exclusivity launches.
• Biosimilar competition does not apply because capivasertib is a small molecule.
• The best excipient opportunities involve qualified supply, co-processed excipients, film-coating systems, and process optimization.
• Patent strength cannot be inferred from the excipient list. Active-ingredient, solid-state, formulation, process, and method-of-use records require separate review.

FAQs

What is the main solubility-related excipient in TRUQAP?

Sodium lauryl sulfate is the principal listed excipient associated with wetting and potential solubility enhancement. Its concentration and interaction with capivasertib are not disclosed in the FDA label.

Can TRUQAP tablets be manufactured without sodium lauryl sulfate?

Potentially, but a substitute formulation would need to demonstrate comparable dissolution, bioequivalence, stability, and manufacturing performance. Particle engineering or another surfactant could be evaluated.

Is TRUQAP a biologic requiring biosimilar competition analysis?

No. TRUQAP contains capivasertib, a small-molecule active ingredient. Generic-drug and ANDA pathways are more relevant than biosimilar pathways.

Could a generic manufacturer use different excipients from TRUQAP?

Yes, subject to FDA requirements. The generic product must demonstrate pharmaceutical equivalence and bioequivalence, and its formulation must meet applicable quality and labeling standards.

Is a capivasertib and fulvestrant fixed-dose product commercially practical?

A true fixed-dose product is technically difficult because capivasertib is oral and fulvestrant is administered by intramuscular injection. A co-packaged treatment regimen is more practical but would require a clear adherence or commercial advantage.

References

1. U.S. Food and Drug Administration. (2023). TRUQAP (capivasertib) prescribing information. AstraZeneca Pharmaceuticals LP. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2023, November 16). FDA approves capivasertib with fulvestrant for breast cancer. https://www.fda.gov
3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm
4. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
5. AstraZeneca. (2024). Annual report and Form 20-F. https://www.astrazeneca.com/investor-relations/annual-reports.html